Navigation Links
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
Date:10/6/2009

s release related July 16, 2009 for more information about the Phase I clinical trial.
  • In a double-blind test, for the purpose of conducting the clinical trial in a completely objective manner, the physicians performing the trial as well as the patients participating in the trial do not know if the substance administered to each individual is the drug being tested or the placebo.
  • The placebo is a substance that does not include the drug being tested (RK-023 in this case).
  • About R-Tech Ueno, Ltd.

    R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innovation," targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent. The company's main product Rescula(R) eyedrop 0.12% is a therapeutic drug for glaucoma and ocular hypertension and has been marketed in Japan since 1994. R-Tech Ueno was the first in the world to take advantage of the substance "prostone" in the development of Rescula(R). Prostone was discovered in 1980 by Dr. Ryuji Ueno, the founder of the company. Rescula(R) eyedrop 0.12% that causes less topical and systemic adverse reactions demonstrates steady ocular pressure-decreasing action by twice-a-day instillation. Such excellent therapeutic effects are realized through its optic nerve protection and ocular blood flow-increasing mechanism.

        Stock Code: No.4573, Osaka Securities Exchange; Hercules
        Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
        Representative Director & President: Yukihiko Mashima
    
    
        Contact:
        Koji Nakamura,
        Business Management Department
        R-Tech Ueno, Ltd.
        Tel: +81-3-3596-8011
        e-mail: koji.nakamura@rtueno.co.jp
        URL: '/>"/>
    SOURCE R-Tech Ueno, Ltd.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
    2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
    3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
    4. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
    5. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
    6. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
    7. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
    8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
    9. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
    10. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
    11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/5/2015)... and TÜBINGEN, Germany ... & Melinda Gates Foundation and CureVac today announced ... invest $52 million (€46 million) in CureVac, a ... technologies. As part of the agreement, the foundation ... to develop prophylactic vaccines based on CureVac,s proprietary ...
    (Date:3/5/2015)... , March 5, 2015  BioPhotas, Inc., an ... that use patented photo-therapeutic technologies to treat skin, muscle ... with the Semper Fi Fund to provide BioPhotas, flagship ... need of pain management solutions.  Commenting ... first Marine who used the Celluma at the Warrior ...
    (Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. ... its second quarter ended January 31, 2015 on Thursday, March ... to discuss the results at 11:00 AM ET. ... approximately 5 to 10 minutes before the beginning of the ... of the call will be available from Thursday, March 12, ...
    Breaking Medicine Technology:The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
    ... up the East Coast as a Category One. As the storm ... the Northeast began to worry. The coastline north of Virginia and ... Jersey all the way up to Massachusetts began mandatory evacuations of ... steps that had not been seen in the city ever before. ...
    ... Pharma , an innovative protein therapeutics company, announced today ... Greve, as vice president, research, and Dr. Andrew Cubitt ... will support aTyr in the development of new breakthrough ... human proteins that possess novel in vivo ...
    Cached Medicine Technology:Hospitals Evacuated in Preparation for Hurricane Irene with Aid of Pulse Oximeter 2aTyr Pharma Expands Leadership Team to Advance New Breakthrough Medicines Based on Physiocrine Biology 2aTyr Pharma Expands Leadership Team to Advance New Breakthrough Medicines Based on Physiocrine Biology 3
    (Date:3/5/2015)... 2015 SuperCloset has released a new video ... aims to teach viewers everything they need to know about ... a SuperPro takes you from seed all the way through ... to how to prune Grow Like a SuperPro will help ... whole series for download for a special introductory price of ...
    (Date:3/5/2015)... At the 7th Annual Mississippi Addiction Conference ... met today in Jackson, Mississippi to listen to keynote ... numerous respected speakers will be William S. Jacobs, ... pain medications have had in today’s opiate overdose and ... is hard to believe that much of the current ...
    (Date:3/5/2015)... 05, 2015 Califia Farms , ... the natural products coffee drinks category[1], today unveils its ... West in Anaheim, Calif. Concentrated Cold Brew (CCB) ... Café, which democratizes the next wave of the coffee-taste ... need to become their own baristas. , Califia ...
    (Date:3/5/2015)... 2015 Supply & Demand Chain Executive ... “Pros to Know” in the supply chain industry, and ... MEBC’s leadership team were included on this year’s list! ... this award due to their hard work, their commitment ... meeting and resolving client needs and challenges. ...
    (Date:3/5/2015)... Minneapolis, Minn. (PRWEB) March 05, 2015 ... authority, invites healthcare organizations to participate in its ... includes data from executive and director-level positions, and ... , Last year’s report featured data on ... 28 independent children’s healthcare organizations and 7 subsidiary ...
    Breaking Medicine News(10 mins):Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Participation Is Now Open For INTEGRATED Healthcare Strategies 2015 Children’s Hospitals Executive Compensation Survey 2
    ... winners and finalists of the 2010 Prix Galien USA and ... issue of Annals of the New York Academy of ... in biopharmaceutical research, recognizes outstanding achievements in improving the global ... Established in 1970, Prix Galien is the most ...
    ... live broadcast from the University of Southampton today (4 ... preventing the spread of antibiotic-resistant organisms, such as MRSA, ... this week,s World Health Day ,Antimicrobial resistance and ... laboratory at the University of Southampton used state-of-the-art fluorescent ...
    ... scientists know this about glioblastoma multiforme: the malignant brain ... in different permutations. In a novel effort ... of University of Cincinnati (UC) researchers has begun sequencing ... They hope that by mapping the various DNA rearrangements ...
    ... - Adolescents represent the majority of people who binge drink. ... surveys indicate that episodes of heavy alcohol drinking within the ... graders, 22 percent of 10th graders, 28 percent of 12th ... adolescence, roughly between 12 to 20 years of age, marks ...
    ... Attention Deficit Hyperactivity Disorder, or ADHD, is widely recognized by ... in place. But as many as six percent of all ... Demonstrating a lack of refined motor skills, children with DCD ... staying organized at school. They appear to be uncoordinated ...
    ... edition of The Royal Marsden Hospital Manual of Clinical ... new format that organises 15 key chapters into four ... content on areas such as risk management and preparing ... nurses from the world-renowned UK centre of excellence, the ...
    Cached Medicine News:Health News:Prix Galien winners published in Annals of the New York Academy of Sciences 2Health News:MRSA eliminated by copper in live global broadcast 2Health News:University of Cincinnati team to track tumor DNA through bloodstream 2Health News:University of Cincinnati team to track tumor DNA through bloodstream 3Health News:Underage binge drinking can create lasting brain changes 2Health News:Clumsy kids who don't 'grow out of it' 2Health News:Patient's journey format drives new edition of vital student nurse manual 2Health News:Patient's journey format drives new edition of vital student nurse manual 3
    Double-ended. 12 mm bayonet shaped blade. 10 mm curved blade....
    15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
    For use with N4096 R, N4097 R and N4098 R. 18 mm wide x 167 mm long. Ten per package. Designated most popular model or size....
    4 mm blade. Flat handle....
    Medicine Products: